Elizabeth Cairns joined Endpoints News as senior biopharma journalist in 2024, and mainly covers clinical data on experimental therapies developed by biotech and pharma companies. Her particular area of interest is cardiometabolic disease, encompassing disorders including obesity, diabetes, heart disease and the liver condition known as MASH. Based in London, she previously worked at Evaluate Vantage and Scrip where she covered biopharma and before that, medical technology. Cairns has a degree in biochemistry from the University of Surrey, UK. In the summer she can be found watching cricket matches, and in the winter sitting on the sofa with a cat and a book.
Sign up for free to read a limited number of articles each month.
About YouPick what newsletters get delivered to your inbox each week.
Want unlimited access? Sign up for a premium subscription plan.